About
UB Therapeutics is a biotechnology company focused on developing a novel therapy for the treatment of multiple myeloma. Multiple Myeloma (MM) is the second most common cancer that affects blood cells, with a 5-year survival rate of approximately 50%.
Technology stack
detected 2026-05-26Est. monthly stack spend~$70/mo
Emailnone
Comments
No comments yet. Be the first to share your take.
Frequently asked
What does UB Therapeutics do?
UB Therapeutics is a biotechnology company focused on developing a novel therapy for the treatment of multiple myeloma. Multiple Myeloma (MM) is the second most common cancer that affects blood cells, with a 5-year survival rate of approximately 50%.
How much funding has UB Therapeutics raised?
UB Therapeutics has raised a total of $10M in funding. The most recent round on record is Seed.
Where is UB Therapeutics headquartered?
UB Therapeutics is headquartered in Cambridge, United States.
When was UB Therapeutics founded?
UB Therapeutics was founded in 2017.
What industry does UB Therapeutics operate in?
UB Therapeutics operates in Life Sciences, Biotech, Oncology, Therapeutics, Drug Discovery, Clinical Trials.
What is UB Therapeutics's current status?
UB Therapeutics's current operating status is: Inactive.